Moderna to Report Fourth Quarter 2025 Financial Results on Friday, February 13, 2026
CAMBRIDGE, MA / ACCESS Newswire / January 26, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a...
Day: January 26, 2026
Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors
Company expands its ADC pipeline and patent estate for novel, differentiated ADCs New pipeline candidate AKTX-102 leverages Akari’s proprietary PH1...
GRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound Structures
Issued Claims Protect Distinct Molecular Designs with Broad Therapeutic Potential Across Inflammatory, Fibrotic, and Autoimmune Diseases LA JOLLA, CA, Jan....
Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
Ongoing clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events, no viral rebounds to date...
SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization
SciSparc intends to target the global multi- billion dollar GERD device market TEL AVIV, Israel, Jan. 26, 2026 (GLOBE NEWSWIRE)...
LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program
Topline data expected in 1Q 2028 Phase 2 bipolar depression trial initiation follows positive Phase 2 results in acute schizophrenia...
Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa
WESTLAKE VILLAGE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing...
Leios Therapeutics and BNC Korea Announce Strategic Collaboration to Accelerate Development of 10XB-101 in South Korea
10XB-101 Being Developed for Focal Fat Reduction and Body ContouringLA JOLLA, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Leios Therapeutics,...
Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)
- Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA...
Primmune Therapeutics Announces Additional Close of Series B Financing
SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Today, Primmune Therapeutics, a biotech company harnessing the power of the innate...
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
CARDAMYST is now conveniently available to patients through retail pharmaciesNational sales force hired with promotional launch in mid-FebruaryExpected $25 copay...
Genyro Signs Exclusive License for “Sidewinder,” a Breakthrough DNA Construction Technology Featured in Nature
A major technological advance in DNA writing enables researchers to construct and create in the language of biology The Genyro...
QHSLab (OTCQB:USAQ) Reports Preliminary Unaudited 2025 Financial Results With Strong Revenue Growth, Expanding Margins, and Significant Debt Reduction
Revenue increased 25% year over year, gross margins expanded to approximately 67%, and convertible debt was substantially eliminatedImproved profitability and...
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on WhiteBIT, a Leading Cryptocurrency Exchange
Listing expected to expand market access and secondary liquidity for Enlivex’s primary digital treasury asset Nes-Ziona, Israel, Jan. 26, 2026...
Invention of DNA “Page Numbers” Opens Up Vast Possibilities for the Bioeconomy
A major technological advance in DNA writing enables researchers to construct and create in the language of biologyPASADENA, Calif., Jan....
Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™
Four abstracts highlighting clinical data and real-world experience with MIPLYFFA accepted for presentation, including an oral presentation by Caroline Hastings,...
Coloplast A/S – Q1 2025/26 Earnings Release – Invitation for conference call on 6 Feb 2026 at 11.00am CET
Friday, 6 February 2026 at 11:00-12:00am CETIn connection with the publication of Coloplast’s interim financial results for Q1 2025/26, to...
Cannara Reports Q1 Fiscal 2026 Results, Delivers New Record Financial Results, Extends Market Share Gains and Advances Disciplined Expansion Strategy
New Record Financial Results: Total revenues of $30.1 million, gross profit before fair value adjustments of $13.5 million or 45% and...
Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET
CAMBRIDGE, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering...
Sharps Technology Reports Strong Solana Staking Income
NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (“STSS” or the “Company”), a medical device company implementing...